Payment overview · 2025
General Payments
$15,769.42
1 reported records · 1 companies
Healthcare provider profile · identity verified
Darrell A Krieger, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CRYSTAL, MN · NPI 1366470825
Verified facts
What the public records show
CMS Open Payments records show Darrell A Krieger, MD received $15,769.42 in general payments during 2025 across 1 reported records.
Boehringer Ingelheim International GmbH accounted for 100.0% of that reported general-payment amount.
Boehringer Ingelheim International GmbH reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 21 records involving 6 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim International GmbH | Unresolved — no canonical attribution shown | $15,769.42 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $15,769.42 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim International GmbH Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 21 supporting records · 6 recipient NPIs · example record 1215868079 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 395 | 121 |
| Lisinopril | Lisinopril | 382 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 340 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 301 | 97 |
| Losartan Potassium | Losartan Potassium | 281 | 92 |
| Simvastatin | Simvastatin | 247 | 63 |
| Omeprazole | Omeprazole | 192 | 61 |
| Metformin Hcl | Metformin Hcl | 182 | 51 |
| Furosemide | Furosemide | 170 | 61 |
| Celecoxib | Celecoxib | 150 | 47 |
| Eliquis | Apixaban | 141 | 39 |
| Gabapentin | Gabapentin | 139 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 127 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 117 | 39 |
| Trazodone Hcl | Trazodone Hcl | 113 | 37 |
| Prednisone | Prednisone | 101 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 95 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 27 |
| Warfarin Sodium | Warfarin Sodium | 93 | 28 |
| Alendronate Sodium | Alendronate Sodium | 90 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 19 |
| Atenolol | Atenolol | 76 | 20 |
| Sertraline Hcl | Sertraline Hcl | 76 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 28 |
| Famotidine | Famotidine | 71 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 16 |
| Mirtazapine | Mirtazapine | 65 | 18 |
| Ezetimibe | Ezetimibe | 63 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 62 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 18 |
| Potassium Chloride | Potassium Chloride | 58 | 20 |
| Allopurinol | Allopurinol | 57 | 19 |
| Donepezil Hcl | Donepezil Hcl | 57 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 23 |
| Tramadol Hcl | Tramadol Hcl | 55 | 18 |
| Nabumetone | Nabumetone | 53 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Glimepiride | Glimepiride | 45 | 14 |
| Buspirone Hcl | Buspirone Hcl | 43 | 15 |
| Lorazepam | Lorazepam | 43 | 15 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 43 | 15 |
| Finasteride | Finasteride | 42 | 13 |
| Alprazolam | Alprazolam | 41 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 32 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 37 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 35 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 11 |
| Metformin Hcl Er | Metformin Hcl | 34 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 32 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 32 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 17 |
| Carvedilol | Carvedilol | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Torsemide | Torsemide | 26 | 12 |
| Cephalexin | Cephalexin | 25 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Cefuroxime | Cefuroxime Axetil | 22 | 21 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Spironolactone | Spironolactone | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 14 |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15,769.42 · 1 records | Boehringer Ingelheim International GmbH | — | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim International GmbH?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error